Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740641 | 0.93 | CASP3 (0.44) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL13253077 | 0.85 | CASP3 (0.48) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL10020438 | 0.84 | MDM4 (0.54) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL1739174 | 0.84 | MDM4 (0.54) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL1740634 | 0.84 | MDM4 (0.45) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL6517147 | 0.83 | CASP3 (0.47) | SLC17A5MDM4TP53CASP3KMT2A | |
| SCHEMBL27129147 | 0.83 | MDM4 (0.49) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL27008576 | 0.83 | MDM4 (0.49) | SLC17A5MDM4TP53MDM2CASP3 | |
| SCHEMBL25835417 | 0.82 | MDM2 (0.42) | SLC17A5MDM4TP53MDM2 | |
| SCHEMBL31197005 | 0.79 | MDM4 (0.54) | SLC17A5MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086633-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF DM1 PROTEIN KINASE (DMPK) COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | SLC17A5 527/4885MDM4 4317/4885TP53 4012/4885 |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | ZFX, DDX39B, DDX21 | SLC17A5 1839/4885MDM4 1086/4885TP53 3439/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | SLC17A5 321/4885MDM4 4563/4885TP53 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.